Cadence plans to try again for FDA approval of Ofirmev

04/19/2010 | Bloomberg Businessweek

Cadence Pharmaceuticals plans to resubmit its pain and fever medicine Ofirmev for FDA approval within the next 30 days. In a meeting with the agency and a third-party manufacturer, the drugmaker said the agency did not request additional data on the drug, an injectable version of acetaminophen that was rejected by the FDA in February because of manufacturing concerns.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN